2019
Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteers
Matuskey D, Dias M, Naganawa M, Pittman B, Henry S, Li S, Gao H, Ropchan J, Nabulsi N, Carson RE, Huang Y. Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteers. Neuropsychopharmacology 2019, 44: 1714-1719. PMID: 30928993, PMCID: PMC6785144, DOI: 10.1038/s41386-019-0379-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsBody Mass IndexBrainFemaleHealthy VolunteersHumansMagnetic Resonance ImagingMaleMiddle AgedPositron-Emission TomographyReceptors, Opioid, kappaSex FactorsSocial ClassConceptsBody mass indexKappa-opioid receptorsPositron emission tomographyAgonist radiotracerKOR systemOpioid receptorsTime-activity curvesBarratt Simplified MeasureAnterior cingulate cortexArterial blood samplingMultilinear analysis-1 (MA1) methodPET imaging studiesKOR levelsMass indexPreclinical modelsFrontal cortexHealthy volunteersRegional time-activity curvesBlood samplingPET scansCingulate cortexImaging studiesEmission tomographyVentral striatumRegional volumesA single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers
Finnema SJ, Rossano S, Naganawa M, Henry S, Gao H, Pracitto R, Maguire RP, Mercier J, Kervyn S, Nicolas J, Klitgaard H, DeBruyn S, Otoul C, Martin P, Muglia P, Matuskey D, Nabulsi NB, Huang Y, Kaminski RM, Hannestad J, Stockis A, Carson RE. A single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. Epilepsia 2019, 60: 958-967. PMID: 30924924, PMCID: PMC6532410, DOI: 10.1111/epi.14701.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnticonvulsantsCarbon RadioisotopesFemaleHealthy VolunteersHumansInhibitory Concentration 50Injections, IntravenousLevetiracetamMagnetic Resonance ImagingMaleMembrane GlycoproteinsNerve Tissue ProteinsNeuroimagingPositron-Emission TomographyProtein BindingPyrrolidinonesConceptsSynaptic vesicle glycoprotein 2AIntravenous brivaracetamHours postdoseBrain penetrationHealthy volunteersDaily oral dosingPositron emission tomography studyFurther clinical studiesEmission tomography studiesPlasma concentration relationshipPositron emission tomography (PET) tracerEmission tomography tracerVivo animal studiesAcute seizuresAntiepileptic drugsTherapeutic dosesCohort 2Oral dosingCohort 1Clinical studiesCohort 3LevetiracetamAnimal studiesRelevant dosesBrivaracetam
2015
Preclinical to Clinical Translation of CNS Transporter Occupancy of TD-9855, a Novel Norepinephrine and Serotonin Reuptake Inhibitor
Smith J, Patil D, Daniels O, Ding YS, Gallezot JD, Henry S, Kim K, Kshirsagar S, Martin W, Obedencio G, Stangeland E, Tsuruda P, Williams W, Carson R, Patil. Preclinical to Clinical Translation of CNS Transporter Occupancy of TD-9855, a Novel Norepinephrine and Serotonin Reuptake Inhibitor. The International Journal Of Neuropsychopharmacology 2015, 18: pyu027. PMID: 25522383, PMCID: PMC4368888, DOI: 10.1093/ijnp/pyu027.Peer-Reviewed Original ResearchMeSH KeywordsAdultAniline CompoundsAnimalsBlood Chemical AnalysisBrainHalf-LifeHumansMagnetic Resonance ImagingMaleModels, BiologicalMorpholinesNeurotransmitter Uptake InhibitorsNorepinephrine Plasma Membrane Transport ProteinsPhenyl EthersPiperidinesPositron-Emission TomographyRadiopharmaceuticalsRats, Sprague-DawleyReboxetineSerotonin Plasma Membrane Transport ProteinsSpinal CordSulfidesConceptsReuptake inhibitorsPositron emission tomographyNorepinephrine transporterSerotonin transporterSerotonin reuptake inhibitorsSingle oral doseUnique clinical profileMonoamine reuptake inhibitorsFuture clinical evaluationRat spinal cordNET occupancySERT occupancyClinical profileOral dosePlasma levelsTransporter profilesClinical evaluationSpinal cordTransporter occupancyCNS penetrationHealthy malesPharmacodynamic modelingNorepinephrineEmission tomographyPET studies
2007
Serotonin transporter binding after recovery from eating disorders
Bailer U, Frank G, Henry S, Price J, Meltzer C, Becker C, Ziolko S, Mathis C, Wagner A, Barbarich-Marsteller N, Putnam K, Kaye W. Serotonin transporter binding after recovery from eating disorders. Psychopharmacology 2007, 195: 315-324. PMID: 17690869, DOI: 10.1007/s00213-007-0896-7.Peer-Reviewed Original ResearchConceptsAnorexia nervosaBulimia nervosaControl womenMethodsPositron emission tomographyHealthy control womenRestricting-type anorexia nervosaRationaleSeveral linesDorsal rapheDistribution volume valuesBP valuesFunction persistEmission tomographyDisorder subjectsResultsAfter correctionMultiple comparisonsTracer kinetic modelNervosaSpecific bindingAffective regulationExaggerated 5-HT1A but Normal 5-HT2A Receptor Activity in Individuals Ill with Anorexia Nervosa
Bailer U, Frank G, Henry S, Price J, Meltzer C, Mathis C, Wagner A, Thornton L, Hoge J, Ziolko S, Becker C, McConaha C, Kaye W. Exaggerated 5-HT1A but Normal 5-HT2A Receptor Activity in Individuals Ill with Anorexia Nervosa. Biological Psychiatry 2007, 61: 1090-1099. PMID: 17241616, DOI: 10.1016/j.biopsych.2006.07.018.Peer-Reviewed Original ResearchConceptsPositron emission tomographyILL ANCerebral blood flowControl womenAnorexia nervosaBlood flowReceptor activityOrbital frontal regionsDorsal raphe nucleusHealthy control womenLateral temporal lobeReceptor-specific radioligandReceptor BPRaphe nucleusPoor responseSerotonin activityTemporal lobeParietal cortexEmission tomographyReceptor functionParietal regionsWomenReceptorsFrontal regionsSignificant increase
2005
Normal Brain Tissue Volumes after Long-Term Recovery in Anorexia and Bulimia Nervosa
Wagner A, Greer P, Bailer U, Frank G, Henry S, Putnam K, Meltzer C, Ziolko S, Hoge J, McConaha C, Kaye W. Normal Brain Tissue Volumes after Long-Term Recovery in Anorexia and Bulimia Nervosa. Biological Psychiatry 2005, 59: 291-293. PMID: 16139807, DOI: 10.1016/j.biopsych.2005.06.014.Peer-Reviewed Original ResearchConceptsWhite matter volumeCerebrospinal fluid volumeControl womenBulimia nervosaLong-term recoveryMatter volumeNormal brain tissue volumeFluid volumeStructural brain abnormalitiesHealthy control womenBrain tissue volumesMagnetic resonance imagingBN subgroupsBrain abnormalitiesAnorexiaResonance imagingBinge/Type anorexiaTissue volumeNervosaWomenDisordersIncreased Dopamine D2/D3 Receptor Binding After Recovery from Anorexia Nervosa Measured by Positron Emission Tomography and [11C]Raclopride
Frank G, Bailer U, Henry S, Drevets W, Meltzer C, Price J, Mathis C, Wagner A, Hoge J, Ziolko S, Barbarich-Marsteller N, Weissfeld L, Kaye W. Increased Dopamine D2/D3 Receptor Binding After Recovery from Anorexia Nervosa Measured by Positron Emission Tomography and [11C]Raclopride. Biological Psychiatry 2005, 58: 908-912. PMID: 15992780, DOI: 10.1016/j.biopsych.2005.05.003.Peer-Reviewed Original ResearchConceptsD2/D3 receptor bindingD3 receptor bindingControl womenAnorexia nervosaPositron emission tomographyDopamine D2/D3 receptor bindingD2/D3 receptor densityEmission tomographyReceptor bindingREC ANHealthy control womenD3 receptor densityEffects of malnutritionDorsal putamenAlterations of weightDorsal caudatePhysical activityReceptor densityDopamine functionMotor activityDA concentrationLines of evidenceWomenNervosaTomography